Additional Relevant Details GlaxoSmithKline plc and Innoviva (formerly Theravance) expect to release initial results from its Phase 3 global study (Salford Lung Study) with 'closed' triple combination treatment FF/UMEC/VI for COPD.  The co-primary endpoints are: to evaluate the effects of FF/UMEC/VI on lung function and health related quality of life compared with budesonide/formoterol after 24 weeks of treatment.  Initial results are expected in the first half of 2016.